RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancer
Portfolio Pulse from
Johnson & Johnson announced results from its Phase 3 MARIPOSA study for RYBREVANT® and LAZCLUZE™, demonstrating a significant overall survival improvement in EGFR-mutated non-small cell lung cancer patients. The combination therapy outperformed osimertinib, with median overall survival not yet reached and a projected survival improvement of over one year.
March 26, 2025 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Positive Phase 3 trial results for RYBREVANT® and LAZCLUZE™ could significantly enhance J&J's oncology portfolio and market position
Successful clinical trial with significant survival benefit suggests potential FDA approval, expanded market share, and increased revenue for J&J's oncology division
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90